Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Body, J.-J.
Right arrow Articles by Bekker, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Body, J.-J.
Right arrow Articles by Bekker, P. J.
Clinical Cancer Research Vol. 12, 1221-1228, February 2006
© 2006 American Association for Cancer Research


Cancer Therapy: Clinical

A Study of the Biological Receptor Activator of Nuclear Factor-{kappa}B Ligand Inhibitor, Denosumab, in Patients with Multiple Myeloma or Bone Metastases from Breast Cancer

Jean-Jacques Body1, Thierry Facon2, Robert E. Coleman3, Allan Lipton4, Filip Geurs1, Michelle Fan5, Donna Holloway5, Mark C. Peterson5 and Pirow J. Bekker5

Authors' Affiliations: 1 Department of Medicine, Institut Jules Bordet, Brussels, Belgium; 2 Service Des Maladies du Sang, CHU de Lille, Lille, France; 3 Cancer Research Centre, Weston Park Hospital, Sheffield, United Kingdom; 4 Division of Hematology/Oncology, Penn State Hershey Medical Center, Hershey, Pennsylvania; and 5 Amgen, Inc., Thousand Oaks, California

Requests for reprints: Jean-Jacques Body, Department of Medicine, Institut Jules Bordet, Rue Héger Bordet 1, B-1000 Brussels, Belgium. Phone: 32-2-541-3303; Fax: 32-2-541-3310; E-mail: jj.body{at}bordet.be.

Purpose: Receptor activator of nuclear factor-{kappa}B ligand (RANKL) is essential for the differentiation, function, and survival of osteoclasts, which play a key role in establishment and propagation of skeletal disease in patients with multiple myeloma or bone metastases as well as many other skeletal diseases. Denosumab (AMG 162), a fully human monoclonal antibody to RANKL, was developed to treat patients with skeletal diseases.

Experimental Design: This was a randomized, double-blind, double-dummy, active-controlled, multicenter study to determine the safety and efficacy of denosumab in patients with breast cancer (n = 29) or multiple myeloma (n = 25) with radiologically confirmed bone lesions. Patients received a single dose of either denosumab (0.1, 0.3, 1.0, or 3.0 mg/kg s.c.) or pamidronate (90 mg i.v.). Bone antiresorptive effect was assessed by changes in urinary and serum N-telopeptide levels. Pharmacokinetics of denosumab also were assessed.

Results: Following a single s.c. dose of denosumab, levels of urinary and serum N-telopeptide decreased within 1 day, and this decrease lasted through 84 days at the higher denosumab doses. Pamidronate also decreased bone turnover, but the effect diminished progressively through follow-up. Denosumab injections were well tolerated. Mean half-lives of denosumab were 33.3 and 46.3 days for the two highest dosages.

Conclusions: A single s.c. dose of denosumab given to patients with multiple myeloma or bone metastases from breast cancer was well tolerated and reduced bone resorption for at least 84 days. The decrease in bone turnover markers was similar in magnitude but more sustained than with i.v. pamidronate.




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
A. Marathe, M. C. Peterson, and D. E. Mager
Integrated Cellular Bone Homeostasis Model for Denosumab Pharmacodynamics in Multiple Myeloma Patients
J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 555 - 562.
[Abstract] [Full Text] [PDF]


Home page
JBJSHome page
L. Gehrig, J. Lane, and M. I. O'Connor
Osteoporosis: Management and Treatment Strategies for Orthopaedic Surgeons
J. Bone Joint Surg. Am., June 1, 2008; 90(6): 1362 - 1374.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
N. Raje, S.-B. Woo, K. Hande, J. T. Yap, P. G. Richardson, S. Vallet, N. Treister, T. Hideshima, N. Sheehy, S. Chhetri, et al.
Clinical, Radiographic, and Biochemical Characterization of Multiple Myeloma Patients with Osteonecrosis of the Jaw
Clin. Cancer Res., April 15, 2008; 14(8): 2387 - 2395.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
A. E. Kearns, S. Khosla, and P. J. Kostenuik
Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease
Endocr. Rev., April 1, 2008; 29(2): 155 - 192.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
D. Vega, N. M. Maalouf, and K. Sakhaee
The Role of Receptor Activator of Nuclear Factor-{kappa}B (RANK)/RANK Ligand/Osteoprotegerin: Clinical Implications
J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4514 - 4521.
[Abstract] [Full Text] [PDF]


Home page
J Am Acad Orthop SurgHome page
C. R. Chu, M. S. McMahon, Y. Ueki, and D. P. Fyhrie
On the Horizon From the ORS
J. Am. Acad. Ortho. Surg., October 1, 2007; 15(10): 636 - 638.
[Full Text] [PDF]


Home page
JCOHome page
A. Lipton, G. G. Steger, J. Figueroa, C. Alvarado, P. Solal-Celigny, J.-J. Body, R. de Boer, R. Berardi, P. Gascon, K. S. Tonkin, et al.
Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases
J. Clin. Oncol., October 1, 2007; 25(28): 4431 - 4437.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J.-J. Body
Breast cancer: bisphosphonate therapy for metastatic bone disease.
Clin. Cancer Res., October 15, 2006; 12(20): 6258s - 6263s.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Lipton
Future treatment of bone metastases.
Clin. Cancer Res., October 15, 2006; 12(20): 6305s - 6308s.
[Abstract] [Full Text] [PDF]


Home page
IBMS BoneKEyHome page
M. R. Smith
Bisphosphonates for Metastatic Bone Disease -- Too Much of a Good Thing?
IBMS BoneKEy, September 1, 2006; 3(9): 24 - 27.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.